Thermo Fisher Scientific's Accelerator Drug Development 360° CDMO and CRO Solutions Boost Time Savings and ROI

Thermo Fisher Scientific's Accelerator Drug Development 360° CDMO and CRO solutions can potentially reduce drug development timelines by up to nearly three years, saving biotech and biopharma companies significant time and money. The integrated services can generate up to $63 million in net financial benefits and a return on investment of up to 113 times the initial investment. The study found that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months.

A recent study by the Tufts Center for the Study of Drug Development (CSDD) has highlighted the substantial time savings and financial benefits that integrated contract development and manufacturing organization (CDMO) and clinical research organization (CRO) services can offer biotech and biopharma companies. The study, supported by Thermo Fisher Scientific Inc., found that these integrated services can reduce drug development timelines by up to nearly three years, representing a significant time savings on the average 10 to 15 years it takes to commercialize a new drug [1].

The study, which modeled the net financial benefit of integrated CDMO-CRO services using a risk-adjusted, discounted cash flow analysis, demonstrated that integrated services can generate up to $63 million in net financial benefits for drug sponsors, with a return on investment of up to 113 times the initial investment. This was achieved by reducing drug development times by up to 34 months across Phase I through Phase III [1].

The benefits of integrated services include streamlined workflows, improved communication, and cross-functional program coordination, which can help address operational inefficiencies and reduce delays. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue due to shortened market exclusivity and deferred market entry [2].

The study's findings provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies. The authors emphasized that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.

Thermo Fisher Scientific, a global leader in serving science, has been at the forefront of this integration, offering its Accelerator Drug Development 360° CDMO and CRO solutions to more than 120 biotech and biopharma companies. The company aims to bring customizable, end-to-end solutions and world-leading expertise to its customers, with a focus on delivering life-changing medicines to patients as quickly as possible.

In summary, the integration of CDMO and CRO services can significantly reduce drug development timelines and generate substantial financial benefits for biotech and biopharma companies. As the study demonstrates, the strategic importance of integrated services as a driver of value cannot be overstated.

References:
[1] https://www.businesswire.com/news/home/20250616585193/en/Tufts-Center-Study-Shows-Significant-Time-Savings-in-Delivering-Therapies-to-Patients-with-Thermo-Fisher-Scientifics-Accelerator-Drug-Development-360-CDMO-and-CRO-Solutions
[2] Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. “Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.” Annals of Operations Research.